
New UC study may help guide treatment of pediatric anxiety
In a comprehensive analysis, SSRIs found to be most effective in treating children and adolescents with anxiety disorder
Researchers from the University of Cincinnati (UC) examined common medications prescribed for children and adolescents with anxiety disorders, to determine which are the most effective and best-tolerated. This study revealed that the selective serotonin reuptake inhibitors (SSRIs) performed best overall compared to other types of medications.
The results, available online in the Journal of Clinical Psychiatry, include the largest amount of data to date for analyses of pediatric anxiety disorder treatments. The study examined more than a dozen medications from 22 randomized controlled trials.
“Clinicians have limited data to help them select among evidence-based medication treatments for their patients with anxiety. This meta-analysis provides guidance in terms of medication-specific differences in efficacy and tolerability among medications that are commonly used to treat pediatric patients with anxiety disorders,” says Jeffrey Strawn, MD, associate professor in the Department of Psychiatry and Behavioral Neuroscience at the UC College of Medicine and lead author on the study.
According to the American Academy of Pediatrics (AAP), anxiety disorders are the most common type of mental health disorder in children. Anxiety affects approximately 8 percent of all children and adolescents. Symptoms of anxiety can include having recurring fears, aversions to social situations or being unable to control worries and can manifest as serious medical conditions: trouble sleeping, difficulty concentrating, even heart and digestive problems.
“Our study synthesizes evidence from multiple individual trials to guide clinicians and patients in deciding which medication to use when treating children and adolescents with anxiety disorders,” said Eric Dobson, MD, a psychiatry resident at the Medical University of South Carolina in Charleston, who conducted the study while a medical student at UC.
The authors identified trials published between 1971 and 2018, comparing 13 commonly used medications with placebo or with other medications—including antidepressants—for the acute treatment of anxiety disorders in children and adolescents. A total of 2,623 patients (average age: 11½ years) had been randomly assigned to receive a medication or receive placebo, and the patients had generalized, separation or social anxiety disorders that was of at least moderate severity.
The researchers looked at the number of patients who responded to treatment as well as the proportion of patients who discontinued the study as a result of adverse events, i.e. side effects. In anxious youth, treatment response was more effective with SSRIs than with serotonin-norepineprhine reuptake inhibitors (SNRIs). SNRIs prolong the activity of- the neurotransmitters serotonin and norepinephrine, while SSRIs act predominantly to prolong the effects of serotonin. In terms of discontinuation and tolerability, SSRIs were the most tolerable class of medication, while tricyclic antidepressants were the least tolerable. Tricyclic antidepressants increase levels of norepinephrine and serotonin, and block the action of the neurotransmitter acetylcholine, which may give rise to some of their side effects.
“This comprehensive evaluation comparing efficacy and tolerability of treatments in pediatric anxiety disorders suggests that SSRIs are superior to SNRIs and all other classes of medications,” says Dobson.
“These findings confirm the recommendations from the American Academy of Child and Adolescent Psychiatry that SSRIs be considered as the first-line medication treatment for anxiety in youth,” adds Strawn.
This research was supported by the National Institute of Mental Health (MH106037–Strawn). Strawn has received research support from the National Institutes of Health (NIH) as well as Edgemont, Forest, Shire, Lundbeck and Neuronetics. He has received material support from and provided consultation to Myriad.
All authors cite no conflicts of interest.
Featured image: Jeffrey Strawn, MD, associate professor of psychiatry and pediatrics. Photo / AHC Communication Services.
Next Lives Here
The University of Cincinnati is classified as a Research I institution by the Carnegie Commission, and is ranked in the National Science Foundation's top 35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
UC researcher launches app to connect patients to lifesaving...
May 7, 2025
A cardiologist and researcher at UC’s College of Medicine joined the Venture Lab at the 1819 Innovation Hub to launch High Enroll, an app that links clinical trials with willing participants.
Growing heart failure epidemic calls for prioritizing primary...
May 5, 2025
A rapidly growing heart failure epidemic calls for prioritizing primary prevention, according to a new scientific statement from the American Heart Association published in Circulation in April. The statement reviews the current evidence for predicting heart failure risk and offers risk-based strategies for heart failure prevention.
Machine learning brings new insights to cell’s role in...
April 30, 2025
Researchers led by the University of Cincinnati’s Anna Kruyer and the University of Houston’s Demetrio Labate have published research in the journal Science Advances applying object recognition technology to track changes in brain cell structure and provide new insights into how the brain responds to heroin use, withdrawal and relapse.